Vanguard Group
SKYE icon

Vanguard Group’s Skye Bioscience SKYE Stock Holding History

Vanguard Group’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$662K Hold
110,348
– – ﹤0.01% 3879
2025
Q3 		$3.47M Buy
110,348
+5,603
+5% +$169K ﹤0.01% 3400
2025
Q2 		$3.5M Sell
104,745
-14,427
-12% -$239K ﹤0.01% 3326
2025
Q1 		$1.52M Buy
119,172
+11,569
+11% +$253K ﹤0.01% 3579
2024
Q4 		$2.44M Buy
107,603
+2,081
+2% +$69.6K ﹤0.01% 3500
2024
Q3 		$3.3M Buy
105,522
+1,319
+1% +$59.2K ﹤0.01% 3412
2024
Q2 		$6.68M Buy
+104,203
New +$9.89M ﹤0.01% 3119

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group's SKYE Position: Q4 2025 in Review

Vanguard Group held its Skye Bioscience (SKYE) position steady in Q4 2025 at 110,348 shares worth $662K. The position accounts for ﹤0.01% of the portfolio, ranked #3879.

Vanguard Group first reported a position in SKYE in Q2 2024 and has held it in 7 quarters since. The position peaked at $6.68M in Q2 2024. 42 funds tracked by Wall St. Rank hold SKYE as of Q4 2025.

  • Vanguard Group held 110,348 shares of Skye Bioscience worth $662K as of Q4 2025.
  • Vanguard Group left its Skye Bioscience share count unchanged in Q4 2025.
  • Skye Bioscience made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #3879 holding.
  • Vanguard Group first reported a position in Skye Bioscience in Q2 2024 and has held it in 7 quarters since.
  • Vanguard Group's Skye Bioscience position peaked at $6.68M in Q2 2024.
  • 42 funds tracked by Wall St. Rank held Skye Bioscience as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.